Genetic evidence has been widely observed as a proxy for success in drug clinical trials, due to an increased understanding of the causal mechanism between drug target and disease. But the abundance and diversity of this data makes inference difficult to achieve at scale. The aim of Open Targets is to have a freely-available and comprehensive platform which aggregates many public datasources to help accelerate the prioritisation of potential therapeutic targets. This seminar will focus on how various streams of genetics data are ingested, processed, and combined into the overall Open Targets evidence framework, and also how researchers may utilise this resource with their own data.
Daniel sstudied a BSc in Genetics at Queen Mary University London, before completing an MPhil in Epidemiology at Cambridge. He then worked as a bioinformatician at the Centre for Cancer Genetic Epidemiology at the University of Cambridge, focused on the genetics of breast and ovarian cancer, before finally moving to work as a computational biologist at Open Targets within the Wellcome Sanger Institute.
Approximate schedule:
6:30: doors open
6:45: chitchat, announcements
7:00: talk starts
7:45: talk ends, adjourn to pub
